Iterum Therapeutics (ITRM) Expected to Announce Earnings on Friday

Iterum Therapeutics (NASDAQ:ITRM) is expected to be releasing its results before the market opens on Friday, February 6th. Analysts expect Iterum Therapeutics to post earnings of ($0.20) per share and revenue of $0.5050 million for the quarter.

Iterum Therapeutics (NASDAQ:ITRM) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07). The company had revenue of $0.39 million during the quarter.

Iterum Therapeutics Price Performance

Shares of Iterum Therapeutics stock opened at $0.31 on Wednesday. The business has a fifty day simple moving average of $0.37 and a two-hundred day simple moving average of $0.57. Iterum Therapeutics has a 1 year low of $0.26 and a 1 year high of $1.62. The company has a market capitalization of $16.73 million, a price-to-earnings ratio of -0.42 and a beta of 2.97.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Iterum Therapeutics in a research note on Monday, December 22nd. Wall Street Zen downgraded shares of Iterum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $9.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Iterum Therapeutics stock. Virtu Financial LLC purchased a new stake in Iterum Therapeutics PLC (NASDAQ:ITRM) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 47,131 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned approximately 0.10% of Iterum Therapeutics at the end of the most recent quarter. 9.21% of the stock is currently owned by hedge funds and other institutional investors.

About Iterum Therapeutics

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).